PHILADELPHIA, March 29, 2018 /PRNewswire/ -- Kehoe Law Firm, P.C. is investigating claims on behalf of investors of Bristol-Myers Squibb Company (NYSE: BMY) to determine whether Bristol-Myers and certain of its officers and/or …
There's no question which stock has performed better recently between GlaxoSmithKline plc (NYSE: GSK) and Bristol-Myers Squibb (NYSE: BMY). Whether you look at 2018 year to date, the last 12 months, the past three years, or the …
Bristol-Myers Squibb has been declining since the open of trade Monday and is now down 3.66 at $55.09. The stock has dropped to an 8-month low.
What was the reason Bristol-Myers Squibb Co (NYSE ... Article printed from InvestorPlace Media, https://investorplace.com/2018/02/bym-stock-earnings-selloff/.
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks …
Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …
Bristol-Myers Squibb Co (NYSE:BMY) stock was down today following the release of its earnings report for the third quarter of 2017. The bad news for BMY stock starts with earnings per share of 75 cents for the third quarter of the year. …
On the one hand, fundamentally BMY is not expensive relative to its peers from a price-to-earnings perspective. It also has a decent balance sheet and runs respectable net margins so there aren’t any obvious issues. But on the other hand, …